ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

paliperidone

Also written as “Paliperidone ER”, “Paliperidone” and “Paliperidone palmitate”.

Its studies are mostly in Schizophrenia · Psychotic Disorders · Bipolar Disorder · Psychomotor Agitation, led by 4 companies.

Drug pagePaliperidone: every studyAll 136 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Aug 30, 2007106 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson1000 open or runningphase 4since Aug 30, 2007Nov 19, 2003none ahead
Luye Pharma Groupits history only30 open or runningphase 1since May 8, 2020May 8, 2020none ahead
CSPC Pharmaceutical Groupits history only21 open or runningno phasesince Sep 30, 2025Sep 30, 2025Dec 31, 2026NCT07493551
Pharmathenits history only10 open or runningphase 2since Jan 26, 2018Jan 26, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Nov 13, 2008.

  1. Aug 17, 2012Phase 4 study in SchizophreniaNCT01670071 · 17 enrolled · Taiwan
  2. Sep 6, 20122 phase 4 studies in SchizophreniaNCT01682161, NCT01685931
  3. Nov 7, 2012Phase 4 study in SchizophreniaNCT01724359 · 95 enrolled · Argentina, Colombia
  4. Sep 10, 2013Phase 1 study in SchizophreniaNCT01942382 · 76 enrolled
  5. Sep 17, 2013Phase 4 study in SchizophreniaNCT01947803 · 353 enrolled · China
  6. Feb 17, 2014Phase 1 study in Psychotic DisordersNCT02087579 · 305 enrolled · United States, Argentina, Belgium and more
  7. Apr 28, 2015Phase 3 study in SchizophreniaNCT02431702 · 337 enrolled · United States, Brazil, Mexico
  8. Jun 2, 2015Phase 2 study in SchizophreniaNCT02462473 · 9 enrolled · United States
  9. Nov 2, 2015Phase 1 study in ImmunoassayNCT02634463 · 81 enrolled · Belgium
  10. Mar 15, 2016Phase 3 study in SchizophreniaNCT02713282 · 306 enrolled · Croatia, Denmark, France and more
  11. Nov 14, 2017Phase 3 study in SchizophreniaNCT03345342 · 841 enrolled · United States, Argentina, Australia and more
  12. Oct 18, 2018Phase 4 study in SchizophreniaNCT03713658 · 34 enrolled · Rwanda
  13. Aug 16, 2019Phase 3 study in SchizophreniaNCT04072575 · 178 enrolled · Argentina, Hong Kong, Italy and more
  14. Jun 22, 2021Phase 4 study in SchizophreniaNCT04940039 · 93 enrolled · Rwanda

TargetBeta

DRD2 →HTR2A →read by rule
“Dopamine D2 receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AripiprazoleruleOtsukaphase 4131
RisperidoneruleJohnson & Johnsonphase 4111
OlanzapineruleEli Lillyphase 476
brexpiprazoleruleOtsukaphase 470
lurasidoneruleSumitomo Pharmaphase 452
iloperidoneruleVanda Pharmaceuticalsphase 415
lumateperoneruleJohnson & Johnsonphase 325

Studies

The newest 60 of 100 Johnson & Johnson leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT04940039Schizophrenia · Rwanda4CompletedApr 16, 202493
NCT04072575Schizophrenia · Argentina, Hong Kong, Italy and more3CompletedMay 3, 2022178
NCT03713658Schizophrenia · Rwanda4CompletedDec 2, 201934
NCT03345342Schizophrenia · United States, Argentina, Australia and more3CompletedMay 8, 2020841
NCT02713282Schizophrenia · Croatia, Denmark, France and more3CompletedMar 26, 2018306
NCT02634463Immunoassay · Belgium1CompletedNov 9, 201681
NCT02462473Schizophrenia · United States2TerminatedJan 20169
NCT02431702Schizophrenia · United States, Brazil, Mexico3CompletedNov 12, 2019337
NCT02087579Psychotic Disorders · United States, Argentina, Belgium and more1CompletedOct 2014305
NCT01947803Schizophrenia · China4CompletedMar 2015353
NCT01942382Schizophrenia1CompletedMar 201076
NCT01724359Schizophrenia · Argentina, Colombia4CompletedNov 200995
NCT01685931Schizophrenia · China4CompletedDec 2014617
NCT01682161Schizophrenia · Korea, Republic of4CompletedSep 2013154
NCT01670071Schizophrenia · Taiwan4TerminatedJun 201517
NCT01662648Schizophrenia3CompletedApr 20081,117
NCT01607762Healthy · Belgium1CompletedApr 201231
NCT01606228Schizophrenia3CompletedDec 2008188
NCT01606254Schizophrenia · Japan2CompletedApr 200856
NCT01577186Schizophrenia4CompletedJun 2009480
NCT01577160Schizophrenia4CompletedApr 2009353
NCT01662310Schizophrenia · China3CompletedApr 2013201
NCT01561898Schizophrenia3CompletedOct 2008228
NCT01541371Schizophrenia3CompletedSep 2009405
NCT01529515Schizophrenia · United States, Colombia, Malaysia and more3CompletedApr 2014509
NCT01527305Schizophrenia · China, Korea, Republic of, Malaysia and more4CompletedDec 31, 2013212
NCT01515423Schizophrenia · United States, Argentina, Australia and more3CompletedFeb 20151,429
NCT01448720Schizophrenia · Brazil, Colombia, Mexico3CompletedDec 2013142
NCT01387542Schizophrenia · Thailand4CompletedSep 201040
NCT01362439Schizophrenia4CompletedMar 2010133
NCT01299389Schizophrenia · Japan, Korea, Republic of, Taiwan3CompletedMay 2012323
NCT01281527Schizophrenia · Austria, Belgium, Croatia and more3CompletedNov 20121,044
NCT01258920Schizophrenia · Japan3CompletedNov 2012201
NCT01193166Schizophrenia4WithdrawnSep 20120
NCT01193153Psychotic Disorders · United States, Bulgaria, India and more3CompletedOct 2013667
NCT01150448Schizophrenia · United States, Belgium, Croatia and more1CompletedJun 2009212
NCT01157351Schizophrenia · United States, Puerto Rico4CompletedDec 2013450
NCT01110317Schizophrenia1Completed49
NCT01081769Schizophrenia · Austria, Belgium, Bulgaria and more3CompletedFeb 2013769
NCT01094249Schizophrenia · United States1CompletedApr 20099
NCT01060228Schizophrenia1Completed24
NCT01050478Psychomotor Agitation · Belgium4CompletedDec 201156
NCT01051531Schizophrenia · Australia, China, Hong Kong and more3CompletedMay 17, 2013546
NCT01010776Schizophrenia · Brazil4CompletedDec 2009223
NCT01009047Schizophrenia · United States, India, Romania and more3CompletedJun 2012228
NCT00934635Schizophrenia · Germany4TerminatedDec 20092
NCT00946985Schizophrenia · United States, Brazil, Bulgaria and more4TerminatedMar 2010163
NCT00915512Schizophrenia · Turkey4CompletedOct 201184
NCT00892489Schizophrenia1Completed80
NCT00892541Schizophrenia1Completed30
NCT00892320Schizophrenia1Completed20
NCT00796835Schizophrenia1Completed50
NCT00796471Schizophrenia1Completed35
NCT00796185Schizophrenia1Completed62
NCT00796029Schizophrenia1Completed5
NCT00791713Schizophrenia1Completed60
NCT00791622Schizophrenia1Completed110
NCT00791401Schizophrenia1Completed47
NCT00791193Schizophrenia1Completed80
NCT00791167Schizophrenia1Completed58

How it is read

Names in the registry

  • “Paliperidone ER”, 39 entries
  • “Paliperidone”, 13 entries
  • “Paliperidone palmitate”, 10 entries
  • “paliperidone palmitate”, 7 entries
  • “Paliperidone Palmitate”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.